Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHRS GH Research	$17.35 +8.5%	$12.72	$6.00 ▼ $20.50	$902.69M	0.96	199,102 shs	153,933 shs
IMCR Immunocore	$35.88 +2.1%	$33.06	$23.15 ▼ $41.53	$1.80B	0.77	340,678 shs	157,445 shs
NTLA Intellia Therapeutics	$12.10 +5.4%	$9.31	$5.90 ▼ $28.18	$1.19B	2.21	3.05 million shs	3.67 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHRS GH Research	+8.13%	+11.69%	+35.93%	+90.00%	+45.66%
IMCR Immunocore	+1.68%	+3.35%	+8.60%	+25.80%	-13.86%
NTLA Intellia Therapeutics	+4.18%	-1.40%	+33.48%	+65.42%	-56.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHRS GH Research	2.0272 of 5 stars	3.5	1.0	0.0	2.6	2.5	0.0
IMCR Immunocore	1.3247 of 5 stars	3.3	0.0	0.0	1.6	2.5	0.0
NTLA Intellia Therapeutics	4.3998 of 5 stars	4.3	1.0	4.7	1.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHRS GH Research	3.00	Buy	$32.00	84.44% Upside
IMCR Immunocore	2.55	Moderate Buy	$58.89	64.15% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	175.68% Upside

Current Analyst Ratings Breakdown

Latest IMCR, GHRS, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
6/2/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/27/2025	IMCR Immunocore	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHRS GH Research	N/A	N/A	N/A	N/A	$3.44 per share	N/A
IMCR Immunocore	$333.58M	5.40	N/A	N/A	$7.20 per share	4.98
NTLA Intellia Therapeutics	$57.88M	21.66	N/A	N/A	$8.56 per share	1.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHRS GH Research	-$38.96M	-$0.79	N/A	N/A	N/A	N/A	-19.20%	-18.40%	9/2/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.43	N/A	N/A	N/A	-6.48%	-5.86%	-2.09%	8/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)

Latest IMCR, GHRS, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IMCR Immunocore	-$0.21	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	N/A	N/A	N/A	$12.26 million	N/A
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/7/2025	Q1 2025	IMCR Immunocore	-$0.35	$0.10	+$0.45	$0.10	$108.82 million	$125.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHRS GH Research	N/A	29.71	29.71
IMCR Immunocore	1.03	6.36	6.31
NTLA Intellia Therapeutics	N/A	4.90	4.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHRS GH Research	56.90%
IMCR Immunocore	84.50%
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
GHRS GH Research	41.60%
IMCR Immunocore	10.40%
NTLA Intellia Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
IMCR Immunocore	320	50.23 million	45.01 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable

IMCR, GHRS, and NTLA Headlines

Recent News About These Companies

Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 5.7% - Here's What Happened

July 16 at 1:00 PM | marketbeat.com

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (NTLA)

...

July 15 at 4:27 PM | marketbeat.com

NTLA - Intellia Therapeutics Inc Trailing Returns - Morningstar

July 12, 2025 | morningstar.comM

Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future

July 10, 2025 | 247wallst.com

Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6.1% - Should You Buy?

July 8, 2025 | marketbeat.com

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 7, 2025 | globenewswire.com

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

July 7, 2025 | zacks.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Eliana Clark Sells 1,022 Shares

July 4, 2025 | insidertrades.com

Intellia Therapeutics Inc. Advanced Charts | NTLA | Barron's

July 4, 2025 | barrons.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Sumitomo Mitsui Trust Group Inc.

July 4, 2025 | marketbeat.com

Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data

July 3, 2025 | msn.com

Insider Selling: Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $10,036.04 in Stock

July 3, 2025 | marketbeat.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube Sells 2,503 Shares

July 3, 2025 | marketbeat.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Director Sells $14,278.81 in Stock

July 2, 2025 | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6.8% - Here's Why

July 2, 2025 | marketbeat.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Moderate Buy" by Brokerages

June 29, 2025 | marketbeat.com

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Nasdaq

June 27, 2025 | nasdaq.com

NTLA - Intellia Therapeutics Inc Chart - Morningstar

June 26, 2025 | morningstar.comM

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

June 25, 2025 | zacks.com

Intellia Therapeutics, Inc. (NTLA) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

NTLA Intellia Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR, GHRS, and NTLA Company Descriptions

GH Research NASDAQ:GHRS

$17.35 +1.36 (+8.51%)

As of 09:30 AM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Immunocore NASDAQ:IMCR

$35.88 +0.73 (+2.06%)

As of 09:30 AM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Intellia Therapeutics NASDAQ:NTLA

$12.10 +0.62 (+5.44%)

As of 09:30 AM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time